Cytomegalovirus (CMV) remains one of the most formidable complications after solid organ transplant (SOT). Limited antiviral options are complicated by their toxicity risk and rising resistance rates, making treatment a challenge. In this activity, Drs. Deepali Kumar and Raymund R. Razonable share practical, evidence-based strategies to manage the most common serious infectious complication after SOT. The faculty are joined by a patient who will speak directly about how her transplant journey was complicated by CMV and what it means for her to navigate this challenging infection on her path towards healing.
Upon completion of this activity, participants should be better able to:
Professor, Department of Medicine
University of Toronto
Program Medical Director, Ajmera Transplant Program
University Health Network
Director, University of Toronto Transplant Institute
Toronto, ON, Canada
Professor, Medicine
Associate Chair of Education, Division of Infectious Diseases
Mayo Clinic
Rochester, MN
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Deepali Kumar, MD, MSc, FRCPC, FAST, has relevant financial relationship(s) with Eurofins-Viracor GSK, Paladin, Pfizer, Takeda (Consultant); GSK, Moderna, Takeda (Grant/Research Support).
Raymund R. Razonable, MD, FIDSA, FAST, has no relevant financial relationship(s) with ineligible companies to disclose.
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-26-002-H01-P)
Type of Activity: Knowledge
Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps:
You must receive a test score of at least 80% and respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
